148 related articles for article (PubMed ID: 37038460)
1. Glucocorticoids selectively affect the memory T cell response to SARS-Cov2 spike in vaccinated and post-infected patients with systemic lupus erythematosus.
Renaudineau Y; Bost C; Abravanel F; Izopet J; Blancher A; Congy N; Treiner E; Sailler L
J Transl Autoimmun; 2023; 6():100200. PubMed ID: 37038460
[TBL] [Abstract][Full Text] [Related]
2. Glucocorticoid use as a cause of non-cellular immune response to SARS-Cov2 Spike in patients with immune system diseases.
Renaudineau Y; Sailler L; Abravanel F; Izopet J; Delourme A; Biotti D; Ciron J; Treiner E; Congy-Jolivet N; Bost C; Blancher A
J Autoimmun; 2022 Dec; 133():102912. PubMed ID: 36115213
[TBL] [Abstract][Full Text] [Related]
3. Novel T cell interferon gamma release assay (IGRA) using spike recombinant protein for COVID19 vaccine response and Nucleocapsid for SARS-Cov2 response.
Renaudineau Y; Abravanel F; Izopet J; Bost C; Treiner E; Congy N; Blancher A
Clin Immunol; 2022 Apr; 237():108979. PubMed ID: 35301104
[TBL] [Abstract][Full Text] [Related]
4. Impact of BNT162b2 mRNA anti-SARS-CoV-2 vaccine on interferon-alpha production by plasmacytoid dendritic cells and autoreactive T cells in patients with systemic lupus erythematosus: The COVALUS project.
Mageau A; Tchen J; Ferré VM; Nicaise-Roland P; Descamps D; Delory N; François C; Mendes C; Papo T; Goulenok T; Charles N; Sacré K
J Autoimmun; 2023 Jan; 134():102987. PubMed ID: 36563528
[TBL] [Abstract][Full Text] [Related]
5. BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus.
Moyon Q; Sterlin D; Miyara M; Anna F; Mathian A; Lhote R; Ghillani-Dalbin P; Breillat P; Mudumba S; de Alba S; Cohen-Aubart F; Haroche J; Pha M; Boutin THD; Chaieb H; Flores PM; Charneau P; Gorochov G; Amoura Z
Ann Rheum Dis; 2022 Apr; 81(4):575-583. PubMed ID: 34607791
[TBL] [Abstract][Full Text] [Related]
6. Evidence of immune response to BNT162b2 COVID-19 vaccine in systemic lupus erythematosus patients treated with Belimumab.
Schiavoni I; Olivetta E; Natalucci F; Olivieri G; Lo Presti A; Fedele G; Stefanelli P; Ceccarelli F; Conti F
Lupus; 2023 Mar; 32(3):394-400. PubMed ID: 36607313
[TBL] [Abstract][Full Text] [Related]
7. SARS-Cov2 acute and post-active infection in the context of autoimmune and chronic inflammatory diseases.
Larionova R; Byvaltsev K; Kravtsova О; Takha E; Petrov S; Kazarian G; Valeeva A; Shuralev E; Mukminov M; Renaudineau Y; Arleevskaya M
J Transl Autoimmun; 2022; 5():100154. PubMed ID: 35434592
[TBL] [Abstract][Full Text] [Related]
8. An interferon-gamma release assay as a novel biomarker in systemic lupus erythematosus.
Thomason JL; Obih UM; Koelle DM; Lood C; Hughes AG
Rheumatology (Oxford); 2020 Nov; 59(11):3479-3487. PubMed ID: 32375180
[TBL] [Abstract][Full Text] [Related]
9. Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α.
Mathian A; Breillat P; Dorgham K; Bastard P; Charre C; Lhote R; Quentric P; Moyon Q; Mariaggi AA; Mouries-Martin S; Mellot C; Anna F; Haroche J; Cohen-Aubart F; Sterlin D; Zahr N; Gervais A; Le Voyer T; Bizien L; Amiot Q; Pha M; Hié M; Chasset F; Yssel H; Miyara M; Charneau P; Ghillani-Dalbin P; Casanova JL; Rozenberg F; Amoura Z; Gorochov G
Ann Rheum Dis; 2022 Dec; 81(12):1695-1703. PubMed ID: 35973806
[TBL] [Abstract][Full Text] [Related]
10. Anti-CII antibody as a novel indicator to assess disease activity in systemic lupus erythematosus.
He C; Mao T; Feng Y; Song T; Qin C; Yan R; Feng P
Lupus; 2015 Nov; 24(13):1370-6. PubMed ID: 26048288
[TBL] [Abstract][Full Text] [Related]
11. [Role of circulating T follicular helper subsets and T follicular helper effector memory cells in systemic lupus erythematosus].
Liang YC; Yao Y; Zhang RJ; Shao M; Sun XL; Shi GX; Gao C; Yu D; He J
Zhonghua Yi Xue Za Zhi; 2019 Jan; 99(3):164-168. PubMed ID: 30669756
[No Abstract] [Full Text] [Related]
12. Cellular and Humoral Immune Responses to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease Patients.
Cerna K; Duricova D; Hindos M; Hindos Hrebackova J; Lukas M; Machkova N; Hruba V; Mitrova K; Kubickova K; Kastylova K; Teplan V; Lukas M
J Crohns Colitis; 2022 Sep; 16(9):1347-1353. PubMed ID: 35358307
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and Safety of mRNA Anti-SARS-CoV-2 Vaccines in Patients with Systemic Lupus Erythematosus.
Mormile I; Della Casa F; Petraroli A; Furno A; Granata F; Portella G; Rossi FW; de Paulis A
Vaccines (Basel); 2022 Jul; 10(8):. PubMed ID: 36016108
[TBL] [Abstract][Full Text] [Related]
14. Effect of SARS-CoV2 infection on disease flares in patients with systemic lupus erythematosus: a case-control study.
Mok CC; Cheung CCL; Chan KL; Tse SM; To CH
Rheumatology (Oxford); 2023 Nov; ():. PubMed ID: 37947324
[TBL] [Abstract][Full Text] [Related]
15. Safety and immune response of a live-attenuated herpes zoster vaccine in patients with systemic lupus erythematosus: a randomised placebo-controlled trial.
Mok CC; Chan KH; Ho LY; Fung YF; Fung WF; Woo PCY
Ann Rheum Dis; 2019 Dec; 78(12):1663-1668. PubMed ID: 31530556
[TBL] [Abstract][Full Text] [Related]
16. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
17. Chemokine CXCL1 as a potential marker of disease activity in systemic lupus erythematosus.
Zeng Y; Lin Q; Yu L; Wang X; Lin Y; Zhang Y; Yan S; Lu X; Li Y; Li W; Xiao Y
BMC Immunol; 2021 Dec; 22(1):82. PubMed ID: 34961474
[TBL] [Abstract][Full Text] [Related]
18. [Investigation of SARS-CoV-2-Specific Humoral and Cellular Immunity Values in Health Care Workers with COVID-19 Disease and Administered with COVID-19 Vaccine].
Keskin AÜ; Dalan AB; Çıragil P; Topkaya AE
Mikrobiyol Bul; 2022 Jul; 56(3):480-492. PubMed ID: 35960239
[TBL] [Abstract][Full Text] [Related]
19. [Increased serum C-C chemokine ligand 19 levels correlated with B cell abnormalities in systemic lupus erythematosus].
Liu HJ; Shi LJ; Hu FL; Yao HH; Li ZG; Jia Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Oct; 49(5):829-834. PubMed ID: 29045964
[TBL] [Abstract][Full Text] [Related]
20. Poor immunogenicity upon SARS-CoV-2 mRNA vaccinations in autoimmune SLE patients is associated with pronounced EF-mediated responses and anti-BAFF/Belimumab treatment.
Faliti CE; Anam FA; Cheedarla N; Woodruff MC; Usman SY; Runnstrom MC; Van TTP; Kyu S; Ahmed H; Morrison-Porter A; Quehl H; Haddad NS; Chen W; Cheedarla S; Neish AS; Roback JD; Antia R; Khosroshahi A; Lee FE; Sanz I
medRxiv; 2023 Jun; ():. PubMed ID: 37398319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
